VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies
Authors:
- Inger van SteenovenISInger van Steenoven
- Barbara NoliBNBarbara Noli
- Cristina CoccoCCCristina Cocco
- Gian-Luca FerriGFGian-Luca Ferri
- Patrick OecklPOPatrick Oeckl
- Markus OttoMOMarkus Otto
- Marleen J. A. Koel-SimmelinkMKMarleen J. A. Koel-Simmelink
- Claire BridelCBClaire Bridel
- Wiesje M. van der FlierWFWiesje M. van der Flier
- Afina W. LemstraALAfina W. Lemstra
- Charlotte E. TeunissenCTCharlotte E. Teunissen
Open Access
- 20 September 2019
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (19) , 4674
Abstract
In a previous proteomic study, we identified the neurosecretory protein VGF (VGF) as a potential biomarker for dementia with Lewy bodies (DLB). Here, we extended the study of VGF by comparing levels in cerebrospinal fluid (CSF) from 44 DLB patients, 20 Alzheimer’s disease (AD) patients, and 22 cognitively normal controls selected from the Amsterdam Dementia Cohort. CSF was analyzed using two orthogonal analytical methods: (1) In-house-developed quantitative ELISA and (2) selected reaction monitoring (SRM). We further addressed associations of VGF with other CSF biomarkers and cognition. VGF levels were lower in CSF from patients with DLB compared to either AD patients or controls. VGF was positively correlated with CSF tau and α-synuclein (0.55 < r < 0.75), but not with Aβ1-42. In DLB patients, low VGF levels were related to a more advanced cognitive decline at time of first presentation, whereas high levels of VGF were associated with steeper subsequent longitudinal cognitive decline. Hence, CSF VGF levels were lower in DLB compared to both AD and controls across different analytical methods. The strong associations with cognitive decline further points out VGF as a possible disease stage or prognostic marker for DLB.Keywords
Funding Information
- Alzheimer Nederland (-)
- Stichting VUmc Fonds (-)
- Stichting Dioraphte (-)
- ZonMw (733050509, 733050102)
- German Federal Ministry of Education and Research (project FTLDc 01GI1007A)
- EU Joint Programme – Neurodegenerative Disease Research (01ED1512)
- German Science Foundation (DFG; SFB 1237)
- Regione Sardegna (2012-CRP-60834)
This publication has 52 references indexed in Scilit:
- NIA‐AA Research Framework: Toward a biological definition of Alzheimer's diseaseAlzheimer's & Dementia, 2018
- Synaptic phosphorylated α-synuclein in dementia with Lewy bodiesBrain, 2017
- Diagnosis and management of dementia with Lewy bodiesNeurology, 2017
- Synaptic failure and α‐synucleinMovement Disorders, 2016
- Lewy body dementiasThe Lancet, 2015
- VGF: An inducible gene product, precursor of a diverse array of neuro-endocrine peptides and tissue-specific disease biomarkersJournal of Chemical Neuroanatomy, 2011
- Pathological roles of α-synuclein in neurological disordersThe Lancet Neurology, 2011
- The Extended Granin Family: Structure, Function, and Biomedical ImplicationsEndocrine Reviews, 2011
- The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementiaActa Neuropathologica, 2010
- α-Synuclein in Lewy bodiesNature, 1997